Virologic and immunologic response to HAART, by age and regimen class

AIDS

Volumn 24, Issue 16, 2010, Pages 2469-2479

  Althoff, Keri N ^a   Justice, Amy C ^b   Gange, Stephen J ^a   Deeks, Steven G ^c   Saag, Michael S ^d   Silverberg, Michael J ^e   Gill, M John ^f   Lau, Bryan ^a   Napravnik, Sonia ^g   Tedaldi, Ellen ^h   Klein, Marina B ⁱ   Gebo, Kelly A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e KAISER PERMANENTE   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h TEMPLE UNIVERSITY   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

Age; CD4 lymphocyte count; HAART; HIV; Viral load

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 78549254488     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833e6d14     Document Type: Article

References (33)

1. Luther VP, Wilkin AM. HIV infection in older adults. Clin Geriatr Med 2007;23:567-583.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2006. In. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten gA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. Grabar S, Kousignian I, Sobel A, Le BP, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004;18:2029-2038.
5. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007;167:684-691.
6. Collaboration of Observational HIV Epidemiologic Research Europe (COHERE) Study Group. Response to combination anti- retroviral therapy: variation by age. AIDS 2008; 22:1463-1473.
7. Knobel H, Guelar A, Valldecillo G, Carmona A, Gonzalez A, Lopez-Colomes JL, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 2001;15:1591-1593.
8. Fleishman JA. Disparities in virologic suppression among patients with HIV infection. Academy Health Annual Research Meeting, San Diego, CA, 2004.
9. Goodkin K, Shapshak P, Asthana D, Zheng W, Concha M, Wilkie FL, et al. Older age and plasma viral load in HIV-1 infection. AIDS 2004;18:S87-S98.
10. Tumbarello M, Rabagliati R, de Gaetano DK, Bertagnolio S, Montuori E, Tamburrini E, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004;4:46.
11. Patterson K, Napravnik S, Eron J, Keruly J, Moore R. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med 2007; 8:406-410.
12. Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008;22:2331-2339.
13. Manfredi R, Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 2000;14:1475-1477.
14. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001;183:1290-1294.
15. Kalayjian RC, Landay A, Pollard RB, Taub DD, Gross BH, Francis IR, et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 2003;187:1924-1933.
16. Cuzin L, Delpierre C, Gerard S, Massip P, Marchou B. Immu- nologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis 2007; 45:654-657.
17. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001;15:735-746.
18. Grimes RM, Otiniano ME, Rodriguez-Barradas MC, Lai D. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 2002;34:1530-1533.
19. Tumbarello M, Rabagliati R, de Gaetano DK, Bertagnolio S, Tamburrini E, Tacconelli E, et al. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS 2003;17:128-131. (Pubitemid 36106310)
20. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004;18:S19-S25.
21. Manfredi R, Calza L, Cocchi D, Chiodo F. Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr 2003; 33:112-114.
22. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. In: 2008. pp. 1-139.
23. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570.
24. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
25. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, et al. A comparison of three highly active antiretroviral treatment strategies consisting of nonnucleoside reverse tran- scriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006;368:2125-2135.
26. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007; 36:294-301.
27. Cuzick J, Edwards R, Segnan N. Adjusting for noncompliance and contamination in randomized clinical trials. Stat Med 1997;16:1017-1029.
28. Cain LE, Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Stat Med 2009;28:1725-1738.
29. Hernan MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 2006;98:237-242.
30. Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004; 75:45-49.
31. Belanger F, Meyer L, Carre N, Coutellier A, Deveau C. Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO cohort (1988-1994). The Seroco Study Group. Int J Epidemiol 1997; 26:1340-1345.
32. Munoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997;11:S69-S76.
33. Bartlett J, Johnson J, Herrera J. Initial therapy with abaca- vir+lamivudine (ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS). XVth International AIDS Conference, Bangkok 2009.